New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 9, 2014
07:09 EDTSGMO, BIIBBiogen and Sangamo collaborate for hemoglobinopathy treatment development
Biogen (BIIB) and Sangamo (SGMO) announced an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin. Sangamo is responsible for all research and development activities, and both companies will perform activities to enable submission of an Investigational New Drug Application for SCD. Biogen will provide Sangamo with an upfront payment of $20M and will reimburse Sangamo for its internal and external research and development program-related costs. Sangamo may also receive additional payments of approximately $300M based on the achievement of certain milestones, as well as double digit royalties on product sales.
News For BIIB;SGMO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
07:04 EDTBIIBIsis Pharmaceuticals earns $9M for advancing ISIS=SMN Rx
Subscribe for More Information
March 4, 2015
07:10 EDTSGMOCowen to hold a conference
35th Annual Health Care Conference is being held in Boston on March 2-4 with webcasted company presentations to begin on March 4 at 8 am; not all company presentations may be webcasted. Webcast Link
February 27, 2015
07:37 EDTBIIBBiogen removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:19 EDTBIIBBiogen, Sobi report Phase 3 Alprolix paediatric study meets primary endpoint
Subscribe for More Information
07:10 EDTBIIBBiogen Idec, Swedish Orphan Biovitrum AB announce positive Alprolix results
Subscribe for More Information
February 26, 2015
08:15 EDTBIIBBiogen shares likely to continue to advance, says RBC Capital
Subscribe for More Information
07:14 EDTSGMOSangamo's XFP Thereapeutic HIV candidate shows positive trial results
Subscribe for More Information
February 25, 2015
06:14 EDTBIIBPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use